Malononitrilamides prevent the development of murine systemic lupus erythematosus-like diseases in BDF1 hybrid mice and MRL/lpr autoimmune mice.
Schorlemmer
H U
HU
Research Laboratory, Hoechst Marion Roussell (HMR), Marburg, Germany.
Brendel
S
S
Bartlett
R R
RR
D000375:Aging / Q000276:immunology; D000480:Alkynes; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D003433:Crosses, Genetic; D004195:Disease Models, Animal; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control*; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007555:Isoxazoles; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000517:prevention & control*; D051379:Mice; D008811:Mice, Inbred DBA; D008817:Mice, Mutant Strains; D009570:Nitriles / Q000627:therapeutic use*
D000480:Alkynes; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D009570:Nitriles; C102911:X 910279; C115284:2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide; D007073:Immunoglobulin E